Yang, Lin

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 746

Dynamic Assignment and Maintenance of Positional Identity in the Ventral Neural Tube by the Morphogen Sonic Hedgehog

Dessaud, E., Ribes, V., Balaskas, N., Yang, L. L., Pierani, A., Kicheva, A., Novitch, B. G., Briscoe, J., & Sasai, N. (2010) · PLoS Biology

Hedgehog Signaling Pathway StudiesDevelopmental Biology and Gene Regulation

Cited by 203

Induction of Androgen Receptor Expression by Phosphatidylinositol 3-Kinase/Akt Downstream Substrate, FOXO3a, and Their Roles in Apoptosis of LNCaP Prostate Cancer Cells

Yang, L., Xie, S., Jamaluddin, M. S., Altuwaijri, S., Ni, J., Kim, E., Chen, Y.-T., Hu, Y.-C., Wang, L., Chuang, K.-H., et al. (2005) · Journal of Biological Chemistry

FOXO transcription factor regulationProstate Cancer Treatment and Research

Cited by 131